
Simulations Plus, Inc.
NASDAQ•SLP
CEO: Mr. Shawn M. O'Connor
Sector: Healthcare
Industry: Medical - Healthcare Information Services
Listing Date: 1997-06-18
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
Contact Information
42505 Tenth Street West, Lancaster, CA, 93534-7059, United States
661-723-7723
Market Cap
$380.97M
P/E (TTM)
-5.9
51.5
Dividend Yield
--
52W High
$37.67
52W Low
$12.39
52W Range
Rank30Top 19.5%
5.1
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q1 2026 Data
Revenue
$18.42M-2.66%
4-Quarter Trend
EPS
$0.03+226.21%
4-Quarter Trend
FCF
$4.23M-411.32%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Revenue Growth 13% Total revenue reached $79.2M, marking a 13% increase, driven by Pro-ficiency acquisition revenue contribution.
Operating Cash Flow Improved Net cash provided by operating activities was $18.1M, showing improvement from $13.3M in the prior fiscal year.
Software Revenue Strong Software revenue grew to $45.8M, representing 58% of total revenue for the fiscal year ended August 31, 2025.
New Sales Model Adoption Pivoted to account-based solution selling model focusing on solving client pain points across the drug development lifecycle.
Risk Factors
Major Impairment Charge Recorded $77.2M in impairments, resulting in a significant net loss of $(64.7M) for the fiscal year period.
Gross Margin Decline Gross margin fell to 58% from 62%, largely attributable to underperformance of Pro-ficiency related revenues.
Intense Market Competition Faces strong competition in life science modeling; rapid AI advances risk demand for proprietary tools and services.
Lengthy Sales Cycles Risk Lengthy sales cycles and client delays risk revenue recognition shortfalls compared to analyst expectations.
Outlook
AI/ML Technology Investment Continued investment in R&D leveraging AI/ML, enhancing ADMET Predictor and generative AI modules for discovery.
Strategic Acquisitions Sought Actively seeking strategic acquisitions to expand pharmaceutical software portfolio and enhance overall service offerings.
Talent Retention Focus Success depends on retaining specialized scientific and engineering personnel amid high industry competition for expertise.
Structure Aligned for Growth Completed reorganization into Software and Services units to align business development for strategic scalability.
Peer Comparison
Revenue (TTM)
$349.88M
$242.28M
$212.07M
Gross Margin (Latest Quarter)
ACIU100.0%
78.3%
76.6%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| CAPR | $1.12B | -16.0 | -62.7% | 0.8% |
| VNDA | $437.88M | -5.2 | -16.8% | 1.0% |
| SLP | $380.97M | -5.9 | -45.5% | 0.4% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-6.4%
Growth Under Pressure
4Q Net Income CAGR
-39.6%
Declining Profitability
Cash Flow Stability
100%
Strong Cash Flow
Research & Insights
Next earnings:Apr 1, 2026
EPS:-
|Revenue:-
Reports
All Years
Form 10-K - FY 2025
Period End: Aug 31, 2025|Filed: Dec 1, 2025|Revenue: $79.18M+13.1%|EPS: $-3.22-744.0%MissForm 10-Q - Q3 2025
Period End: May 31, 2025|Filed: Jul 15, 2025|Revenue: $20.36M+9.8%|EPS: $-3.35-2193.8%MissForm 10-Q - Q2 2025
Period End: Feb 28, 2025|Filed: Apr 4, 2025|Revenue: $22.43M+22.5%|EPS: $0.15-25.0%MissForm 10-Q - Q1 2025
Period End: Nov 30, 2024|Filed: Jan 8, 2025|Revenue: $18.92M+30.5%|EPS: $0.01-89.4%MissForm 10-K - FY 2024
Period End: Aug 31, 2024|Filed: Oct 30, 2024|Revenue: $70.01M+17.5%|EPS: $0.50+0.0%BeatForm 10-Q - Q3 2024
Period End: May 31, 2024|Filed: Jul 8, 2024|Revenue: $18.54M+14.2%|EPS: $0.16-20.0%BeatForm 10-Q - Q2 2024
Period End: Feb 29, 2024|Filed: Apr 5, 2024|Revenue: $18.31M+16.2%|EPS: $0.20-4.8%BeatForm 10-Q - Q1 2024
Period End: Nov 30, 2023|Filed: Jan 5, 2024|Revenue: $14.50M+21.2%|EPS: $0.10+58.8%Meet